{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:28Z","timestamp":1789391668946,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jacc.2017.07.745","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T16:18:18Z","timestamp":1504628298000},"page":"1785-1822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":314,"title":["2017 Focused Update of the 2016\u00a0ACC\u00a0Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in\u00a0the Management of Atherosclerotic Cardiovascular Disease Risk"],"prefix":"10.1016","volume":"70","author":[{"given":"Donald M.","family":"Lloyd-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim K.","family":"Birtcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"David D.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondra M.","family":"DePalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo B.","family":"Minissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Orringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Sidney C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2017.07.745_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib6","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib9","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on\u00a0Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib10","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on\u00a0Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.jacc.2017.07.745_bib11","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2017.07.745_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M15-0840","article-title":"Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline","volume":"163","author":"Downs","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.07.745_bib15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib19","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib20","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib21","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on\u00a0Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.07.745_bib23","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.07.745_bib24","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.07.745_bib25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2014.02.033","article-title":"Statin intolerance","volume":"113","author":"Ahmad","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.07.745_bib27","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.07.745_bib28","first-page":"CD009744","article-title":"Niacin for primary and secondary prevention of cardiovascular events","volume":"6","author":"Schandelmaier","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2017.07.745_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1373\/clinchem.2008.117929","article-title":"Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women","volume":"55","author":"Mora","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2017.07.745_bib30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","article-title":"Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications","volume":"62","author":"Martin","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.atherosclerosis.2015.03.004","article-title":"Variability of the LDL-C lowering response to ezetimibe and ezetimibe\u00a0+ statin therapy in hypercholesterolemic patients","volume":"240","author":"Descamps","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2017.07.745_bib32","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A\u00a052-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.07.745_bib34","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FJC.0b013e31823a109f","article-title":"Efficacy of colesevelam on lowering glycemia and lipids","volume":"59","author":"Aggarwal","year":"2012","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2017.07.745_bib36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.07.745_bib37","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.07.745_bib38","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.07.745_bib39","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.07.745_bib40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.07.745_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11883-015-0516-7","article-title":"Lipoprotein apheresis","volume":"17","author":"Bhoj","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2017.07.745_bib42","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.07.745_bib43","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib44","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib45","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","article-title":"Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of\u00a0CORONA and GISSI-HF","volume":"17","author":"Feinstein","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2017.07.745_bib46","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.07.745_bib47","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.745_bib48","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2017.07.745_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"Giugliano","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2017.07.745_bib56","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.07.745_bib57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9149(92)91264-5","article-title":"Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia","volume":"70","author":"Superko","year":"1992","journal-title":"Am J Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717388988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717388988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:13:37Z","timestamp":1760015617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717388988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":47,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0735109717388988"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2017.07.745","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2017 Focused Update of the 2016\u00a0ACC\u00a0Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in\u00a0the Management of Atherosclerotic Cardiovascular Disease Risk","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.07.745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}